English
Home > Products > CAS NO 158355-41-0

China CAS NO 158355-41-0 Factory

Our commission should be to provide our end users and clients with very best excellent and aggressive portable digital products and solutions for CAS NO 158355-41-0,158355-41-0,1,1,7-trichloro-1-hepten-3-one, We will do our greatest to meet or exceed customers' demands with top quality items, advanced concept, and productive and timely company. We welcome all customers.
CAS NO 158355-41-0, Adhering to the principle of "Enterprising and Truth-Seeking, Preciseness and Unity", with technology as the core, our company continues to innovate, dedicated to providing you with the highest cost-effective products and meticulous after-sales service. We firmly believe that: we are outstanding as we are specialized.

Related Products

Hot Products

  • 3-Amino-1,2,3,4-tetrahydrocarbazol

    3-Amino-1,2,3,4-tetrahydrocarbazol

    Product Name:3-Amino-1,2,3,4-tetrahydrocarbazol
    Molecular Formula:C12H14N2
    Molecular Weight:186.25
    CAS Registry Number:61894-99-3
  • Tenofovir disoproxil fumarate

    Tenofovir disoproxil fumarate

    Product Name:Tenofovir disoproxil fumarate
    Molecular Formula:C23H34N5O14P
    Molecular Weight;635.52
    CAS Registry Number;202138-50-9
  • 6-alpha-Fluoro-isoflupredone

    6-alpha-Fluoro-isoflupredone

    Product Name:6-alpha-Fluoro-isoflupredone
    Molecular Formula:C21H26F2O5
    Molecular Weight:396.42
    CAS Registry Number:806-29-1
  • Ledipasvir acetone

    Ledipasvir acetone

    Product Name:Ledipasvir acetone
    Molecular Formula:C52H60F2N8O7
    Molecular Weight;947.1
    CAS Registry Number;1441674-54-9
  • Ethyltriphenylphosphonium bromide

    Ethyltriphenylphosphonium bromide

    Product Name:Ethyltriphenylphosphonium bromide
    Molecular Formula:C20H20BrP
    Molecular Weight:371.25
    CAS Registry Number:1530-32-1
  • Methyl salicylate

    Methyl salicylate

    Product Name:Methyl salicylate
    Molecular Formula:C8H8O3
    Molecular Weight;152.15
    CAS Registry Number;119-36-8
  • Related Blog
  • Reviews

  • Baloxavir marboxil

    Baloxavir marboxil is used to treat flu symptoms caused by influenza virus in people who have had symptoms for no more than 48 hours. Baloxavir marboxil will not treat the common cold. Baloxavir marboxil is for adults and children who are at least 12 years old and weigh at least 88 pounds (40 kilograms).

  • TOP 8 Linezolid intermediate maker

    Sandoo Pharmaceuticals and Chemicals Co.,Ltd was established in 2009, with a creative and active team, located in Ningbo, China. We have been specialized in exporting and importing pharmaceutical intermediates and chemical products as well as API for more than 10 years, covering more than 10 countries.

  • Differences Between Pharmaceutical Raw Materials, Excipients and Pharmaceutical Intermediates

    In the pharmaceutical industry, there are various names of raw materials, such as pharmaceutical raw materials, pharmaceutical intermediates and pharmaceutical excipients in the process of pharmaceutical production. This article will take everyone to recognize these three concepts.

  • What is the difference between API and FDF in pharma？

    In the pharmaceutical industry, you might hear the terms “FDF” and “API” frequently used in reference to products. We surely understand this type of jargon, but we certainly can see how the general public would feel overwhelmed looking at those kinds of terminology abbreviations. This article is for explaining the difference between API and FDF. For reference, they mean, respectively, “finished dosage form” and “active pharmaceutical ingredient.”

  • Everything You Need To Know About Active Pharmaceutical Ingredients (API In Pharma)

    Sandoo, as a professional API manufactruer in China, we produces a wide range of active pharmaceutical ingredients which can be used in the production of medicines in different applications. Our products are produced under strict procedures and cGMP (Current Good Manufacturing Practices). In addtion, we can also customize new pharmaceutical compounds for new drugs.

  • FDA approves lorlatinib for second- or third-line treatment of ALK-positive metastatic NSCLC

    On November 2, 2018, the Food and Drug Administration granted accelerated approval to lorlatinib (LORBRENA, Pfizer, Inc.) for patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) whose disease has progressed on crizotinib and at least one other ALK inhibitor for metastatic disease or whose disease has progressed on alectinib or ceritinib as the first ALK inhibitor therapy for metastatic disease.

Send Inquiry

Hit enter to search or ESC to close
X
We use cookies to offer you a better browsing experience, analyze site traffic and personalize content. By using this site, you agree to our use of cookies. Privacy Policy
Reject Accept